PDB81 - DAPAGLIFLOZIN IS COST-EFFECTIVE COMPARED TO DPP-4 INHIBITORS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE NETHERLANDS
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2018 |
| Reihe/Periodikum: | Value in Health ; volume 21, page S132 ; ISSN 1098-3015 |
| Verlag/Hrsg.: |
Elsevier BV
|
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-29167874 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://dx.doi.org/10.1016/j.jval.2018.09.786 |
